Skip to main content

Table 2 Patient characteristics

From: Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up

  Retrospective cohort Prospective cohort Combination cohort
Non-PCa PCa Non-PCa PCa Non-PCa PCa
Patients (%) 94 (15.3%) 520 (84.7%) 189 (47.7%) 207 (52.3%) 283 (28.0%) 727 (72.0%)
Mean age (year) 64 (41–84) 64 (45–78) 69 (45–86) 69 (39–88) 68 (41–86) 65 (39–88)
Patients with other cancers (%) 1 (1.1%) 4 (0.8%) 2 (1.1%) 1 (0.5%) 3 (1.1%) 5 (0.7%)
Gleason score (%)       
Group 1: ≤ 6 (≤ 3 + 3) NA 124 (23.8%) NA 39 (18.8%) NA 163 (22.4%)
Group 2: 7 (3 + 4) NA 218 (41.9%) NA 54 (26.1%) NA 272 (37.4%)
Group 3: 7 (4 + 3) NA 136 (26.2%) NA 55 (26.6%) NA 191 (26.3%)
Group 4: 8 (4 + 4, 3 + 5, 5 + 3) NA 17 (3.3%) NA 30 (14.5%) NA 47 (6.5%)
Group 5: 9 or 10 (4 + 5, 5 + 4, or 5 + 5) NA 25 (4.8%) NA 29 (14.0%) NA 54 (7.4%)
Mean PSA (ng/mL) 10.1 6.1 10.6 67.9 10.51 65.0